From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|January 18, 2022
Daily OTC Pearl: Emetrol
Author(s)Saro Arakelians, PharmD
Advertisement
OTC/Lifestyle Pearl of the Day: Emetrol
Indication: Emetrol is used to treat an
Insight:
- Active ingredients: Dextrose (glucose) 1.87 g, levulose (fructose) 1.87g, and phosphoric acid 21.5 mg.
- This medication contains phosphoric acid/dextrose/fructose.
- Measure liquid doses carefully. Use the measuring device that comes with Emetrol.
- Do not mix with any liquid.
- Avoid if you have an allergy to fructose,
dextrose , phosphoric acid, or any other part of Emetrol. - Store at the room temperature until the manufacturer expiration date.
Sources:
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Glucose Monitoring: Timing Makes Every Reading Count
3
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5